

Biofrontera AG
("Biofrontera" or "the Company")

Biofrontera launches new addition Belixos® Gel to its derma-cosmetic line

Leverkusen, Germany, 05. December 2014 - Biofrontera (FSE / AIM: B8F), the specialist for sun induced skin cancer, has this week launched the third product of its derma-cosmetic line Belixos®, a cooling and cleaning day care gel designed for situations of increased sebum production.

Belixos® Gel was developed for the special needs of inflamed, reddened skin prone to impurities, the ideal basic care for rosacea and acne. To minimize the risk for sensitive reactions and skin irritations the gel formulation was reduced to just a few high-value ingredients. The formulation causes a cooling sensation and combines the extracts of cinnamon bark in the Sepicontrol A5 complex and mahonia aquifolium with Biofrontera's innovative biocolloid technology.

The extract of mahonia relieves inflammation, redness and itching, typical signs of rosacea. The active ingredient complex Sepicontrol A5 with cinnamon bark has antibacterial activity and removes callused skin, regulates sebum and clears congested sebaceous glands.

As with the other products in the Belixos® derma-cosmetic series in cream and liquid formulations, the underlying biocolloid technology causes an optimized penetration of this unique ingredient combination from traditional medicinal plants extracts.

Commenting, Prof. Dr. Hermann Lübbert, CEO of Biofrontera, said: "The new Belixos® Gel compliments the Company's existing derma-cosmetic products which successfully bring together the benefits of natural ingredients, already recognized for their efficacy, and Biofrontera's innovative biocolloid formulation, effectively delivering excellent cosmetic properties to the skin."

Ends.

For inquiries, please contact:

Biofrontera AG

Thomas Schaffer, CFO

+49 (0) 214 87 63 20

press@biofrontera.com

IR Germany: Brainwell Asset Solutions

Jürgen Benker

+49 (0) 152 08931514

Press release

Nomad and Broker: Shore Capital +44(0) 20 7408 4090
Bidhi Bhoma / Toby Gibbs

IR UK: Seton Services +44(0) 20 7603 6797
Toni Vallen

Financial PR: Gable Communications +44(0) 20 7193 7463
John Bick +44 (0)7872 061007
bio@gablecommunications.com

Background:

The **Biofrontera Group** (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is **Ameluz**[®], a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz[®] to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.

The company also markets the Belixos[®] dermatological range of cosmetics. Belixos[®] contains a combination of active substances extracted from plants, relieves itching and redness and is used for the regenerative treatment of chronic skin conditions such as atopic dermatitis or psoriasis. At the moment, Belixos[®] is available as a cream and scalp tonic.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.

www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.